Zeria/Tillotts in $100m-plus deal for CPP's FAP drug

Tillotts Pharma and its parent Zeria have acquired development and commercialization rights in Europe and Japan to a therapy for familial adenomatous polyposis (FAP) being developed by Cancer Prevention Pharmaceuticals (CPP).